Lion's Mane for Gut Health: What the Research Shows

Lion's Mane & Gut Health

26 studies

A 2025 systematic review of 26 studies confirmed gut health as one of lion's mane's validated benefit areas — spanning gastroprotection, microbiome modulation, and barrier function.

Menon et al., Frontiers in Nutrition, 2025

2023

Year gastroenterologists published a GI-specific lion's mane review

n=13

Participants in the largest human gut health pilot study

3

Distinct gut mechanisms with preclinical support

Menon et al., Frontiers in Nutrition, 2025

View as image ↗

In 2023, a team of Italian gastroenterologists published a review of Hericium erinaceus — the mushroom commonly called lion's mane — in the World Journal of Gastroenterology. Not a supplement blog. Not a wellness newsletter. A peer-reviewed GI journal, written by physicians who specialize in digestive disease.

Their conclusion: traditional uses of lion's mane for stomach and gut complaints are supported by emerging preclinical evidence, with encouraging early human data. They also named exactly where the gaps are.

That review — Gravina et al., 2023 — is the most authoritative piece of lion's mane gut health research published to date.^[1] It is cited in none of the consumer content on this topic.

This article walks through what the research actually shows: the three gut mechanisms studied, the specific findings behind each, and the honest gap between laboratory data and clinical evidence. For a foundational overview of what lion's mane is and how its bioactive compounds work, see our science-based lion's mane overview.

Three Ways Lion's Mane Affects the Gut

Lion's mane gut health research organizes around three distinct mechanisms, each studied independently in laboratory and animal work.

First, it acts as a gastroprotective agent: compounds in the mushroom — primarily polysaccharides from the mycelium — protect the stomach lining from inflammatory damage and reduce markers of gastric cell injury.

Second, it shows antimicrobial activity against Helicobacter pylori — the bacterium that causes most stomach ulcers and chronic gastritis. Both cell-culture experiments and mouse models have demonstrated meaningful inhibition.

Third, it functions as a prebiotic, promoting growth of beneficial gut bacteria (including short-chain-fatty-acid–producing species) while reducing pathogenic bacteria. This pattern appears in animal studies and in the one available human pilot.

All three mechanisms are documented in the Gravina 2023 GI review.^[1] The strongest evidence sits in preclinical work. Human data is early and limited to a single small study.

Three GI Mechanisms · One Evidence Map

Where Lion’s Mane Gut Research Actually Stands

The gut-health case rests on three separately studied mechanisms. Each is tagged with the most human-like organism in which it has been demonstrated. Only the microbiome pillar has any direct human evidence — and that is a single uncontrolled pilot.

1

Gastroprotection

Molecular signature

gastric cell growth ↓

An isolated mycelial polysaccharide (EP-1) suppressed the growth of transformed, pre-cancerous gastric epithelial cells and forced them into cell-cycle arrest — the readout for anti–chronic-atrophic-gastritis activity. Related culture-broth extracts showed anticancer activity against gastric and other GI cancer cells and in mouse xenografts.

AnimalRefs 4, 5

2

H. pylori control

Molecular signature

MIC ≈ 2 mg/mL · adhesion ↓

An ethanolic extract inhibited every one of six H. pylori strains tested, blocked the bacterium from adhering to human gastric cells, and lowered colonisation in mice — a two-front effect (direct kill plus anti-adhesion). All preclinical; no human eradication trial exists.

AnimalRefs 1, 7

3

Microbiome & barrier

Molecular signature

SCFA producers ↑ · ZO-1 · occludin

Extracts relieved colitis and promoted beneficial gut bacteria in rats, restored tight-junction proteins (ZO-1, occludin) in immunocompromised mice, and confirmed colitis relief in cynomolgus monkeys. A 13-person human pilot showed a matching rise in short-chain-fatty-acid–producing bacteria — the only direct human data point.

Human pilotRefs 3, 6, 8, 9

“Highest organism” is the most human-like model in which each mechanism has been shown. Gastroprotection and H. pylori control remain cell- and animal-level; only the microbiome pillar reaches a human pilot, and no rung above it has been climbed for any gut condition.

Source: Gravina et al. (2023); Xie et al. (2021); Wang et al. (2015); Li et al. (2014); Diling et al. (2017); Wang et al. (2019); Tian et al. (2023, barrier); Ren et al. (2023)

The Gastroenterologist Review That Consumer Sites Missed

In traditional Chinese medicine, Hericium erinaceus was prescribed specifically for epigastric pain — the kind of stomach discomfort that often signals chronic gastritis or ulcer disease. This was a documented clinical indication, used for centuries, that Gravina and colleagues examined systematically.

Their 2023 review in the World Journal of Gastroenterology synthesized the available evidence across four areas: gastritis and gastroprotection, H. pylori inhibition, inflammatory bowel disease, and gut microbiota modulation.^[1]

Their overall conclusion: the preclinical evidence is consistent and mechanistically coherent. Early human pilot data is encouraging. Clinical trials in humans are the missing piece.

What makes this review different from general lion's mane overviews — and why its source matters — is the journal. The World Journal of Gastroenterology is read by GI physicians, hepatologists, and gastroenterology researchers. A review published here must survive scrutiny from readers who know the field. It is not an integrative medicine publication predisposed to finding plant extracts promising.

Gravina's team framed lion's mane GI research as an area where traditional use is being progressively validated by laboratory science — not as a supplement with proven clinical efficacy. That distinction is important. It means the research is credible enough for a gastroenterology journal to take seriously while still being pre-clinical in the areas that matter for human health decisions.

The Menon et al. 2025 systematic review of 26 studies — which included 5 RCTs, 15 laboratory studies, and 3 pilot clinical trials — confirmed gut health as a validated benefit area alongside neuroprotection, and reported no serious adverse effects across clinical studies.^[2] Two independent systematic reviews, one authored by GI specialists and one a broader evidence synthesis, reach the same conclusion: the mechanisms are real, the human data needs to grow.

Protecting the Stomach Lining: What the Chronic Gastritis Data Shows

Chronic atrophic gastritis is not ordinary indigestion. It is a condition where the stomach lining progressively loses its glandular cells over years — a pre-malignant condition that increases gastric cancer risk over time. The distinction matters because it marks lion's mane's gastroprotective research as relevant beyond general digestive comfort.

Wang et al. (2015) isolated a polysaccharide — designated EP-1 — from cultured Hericium erinaceus mycelium and tested it in a chronic atrophic gastritis cell model built from human gastric epithelial (GES-1) cells that had been chemically transformed into abnormal, pre-cancerous "MC" cells.^[4] EP-1 significantly inhibited the growth of these transformed cells and drove them into cell-cycle arrest — the change the researchers used as their readout of anti–chronic-atrophic-gastritis activity.

The relevance is specific rather than general. Chronic atrophic gastritis is defined by exactly this kind of abnormal transformation and loss of normal gastric gland cells; EP-1 acted directly on that transformed-cell population. This is a cell-model result — it shows the polysaccharide can constrain abnormal gastric-cell growth in a dish, not that it reverses gastritis in a living stomach.

Li et al. (2014) took a different angle, testing two H. erinaceus culture-broth extracts (HTJ5 and HTJ5A) against human gastrointestinal cancer cell lines — including gastric, colorectal, and liver cancer — and against tumor xenografts in mice.^[5] Both extracts showed anticancer activity against the gastric and other GI cancer cells, and the effect carried over into the in-vivo xenograft models. This is early-stage laboratory and animal research, not human data. Its significance is in biological plausibility: the compounds in lion's mane can interact with gastric tissue in ways that might be relevant to precancerous and cancerous processes.

Neither Wang 2015 nor Li 2014 involved human patients. They provide biological plausibility and mechanistic explanation for the traditional gastroprotective use. For a detailed breakdown of the gastritis-specific evidence, see the dedicated piece on lion's mane and gastritis.

H. pylori and Lion's Mane: An Overlooked Research Thread

Roughly 44% of the global adult population carries Helicobacter pylori in the stomach lining. The bacterium causes the majority of chronic gastritis cases, drives most gastric ulcers, and is classified by the World Health Organization as a Group 1 carcinogen — the same category as tobacco.

The Gravina 2023 review identified H. pylori inhibition as one of the documented areas of lion's mane GI research.^[1] The review draws on multiple in vitro experiments and mouse models. In one representative study, an ethanolic H. erinaceus extract inhibited all six H. pylori strains it was tested against — with a minimum inhibitory concentration of roughly 2 mg/mL — reduced the bacterium's ability to adhere to human gastric cells, and lowered H. pylori colonization in mice.^[7]

What makes the signal notable is its breadth and its dual action. The extract suppressed every strain it was tested against rather than a single laboratory isolate, and it worked on two fronts at once — inhibiting the bacterium directly and blocking the adhesion step it needs to establish infection. Most natural compounds studied for H. pylori are evaluated only for direct kill, so the anti-adhesion activity is a mechanistically distinct addition.

The important caveat is the same as for every other lion's mane gut finding: no human trial has tested lion's mane for H. pylori eradication. The concentrations that inhibit H. pylori in cell culture may not be achievable through normal oral supplementation. In vitro inhibition of a bacterium does not establish that a supplement will eradicate it in the human stomach — a very different and more challenging biological environment.

This is a research direction with an interesting preclinical signal. It is not a treatment finding. For the full H. pylori evidence including MIC (minimum inhibitory concentration) values and in vivo mouse data, see the dedicated piece on Hericium erinaceus and H. pylori.

The Prebiotic Effect: How Lion's Mane Shifts Gut Bacteria

The relationship between lion's mane and gut microbiota is mechanistically interesting beyond its own effects — because gut bacteria composition connects several of the other gut mechanisms.

Gut microbiota (the community of bacteria living in the intestine) influences inflammation levels, how well the intestinal wall holds together, and how the immune system behaves. A shift toward Lactobacillus and Bifidobacterium — two bacterial genera consistently linked to gut health — has downstream effects on all three.

Diling et al. (2017) studied H. erinaceus extracts in rats with chemically induced (TNBS) colitis — a standard laboratory model of inflammatory bowel disease.^[6] The extracts reduced colitis severity through two simultaneous pathways: they modulated immune signaling — lowering TNF-alpha and NF-κB activity while raising the anti-inflammatory regulators IL-10 and Foxp3 — and they shifted gut bacteria composition, promoting the growth of beneficial gut bacteria over the disrupted community seen in untreated animals.

The dual mechanism matters because gut inflammation and gut bacteria imbalance reinforce each other. Inflammation disrupts the bacterial community; a disrupted bacterial community perpetuates inflammation. An intervention that addresses both simultaneously would theoretically be more effective than one targeting either alone.

Menon et al.'s 2025 systematic review confirmed this prebiotic-like pattern as one of lion's mane's validated mechanisms across multiple study designs.^[2] The review highlights H. erinaceus's promotion of short-chain-fatty-acid–producing gut bacteria as one of its documented effects — a pattern seen across laboratory, animal, and early human research.

The One Human Study: 13 People, Two Weeks, and What Changed

Most of the gut health research on lion's mane comes from animal models. The human evidence is thin. That should be stated plainly, because it significantly limits what can be concluded from this body of literature.

Xie et al. (2021) conducted the most directly relevant human study available: a pilot in 13 healthy adults who consumed lion's mane powder for two weeks.^[3] The researchers profiled gut bacteria composition by 16S rRNA sequencing and tracked a panel of routine blood biochemical markers before and after.

What they found: gut bacteria diversity increased. Short-chain-fatty-acid–producing bacteria — including Faecalibacterium prausnitzii and Eubacterium rectale, species associated with a healthy gut lining — became more abundant, while several potential pathobionts declined. The microbiota shifts tracked with changes in blood chemistry such as alkaline phosphatase, LDL, and uric acid.

That is the entire human data set for lion's mane and gut health.

Thirteen people for two weeks is not a clinical trial. It is a pilot — its value is signal generation, not proof of efficacy. What Xie 2021 shows is that the bacteria shifts observed in animal models appear to occur in humans too, on a short time horizon, in a small group. That is a meaningful signal. It is not sufficient to establish clinical benefit for any gut condition.

Why this distinction matters: supplement brands citing lion's mane for gut health often present preclinical animal data as if it reliably predicts human outcomes. It doesn't — not because animal research is without value, but because many compounds that work in mice fail in humans. The Xie pilot suggests lion's mane may be one of those that does translate, but that needs confirmation in larger, controlled trials before confidence is warranted.

The Examine.com entry on lion's mane is notable here: it acknowledges the gut microbiome data from Xie 2021 while explicitly noting that a 13-person study requires more research before conclusions can be drawn. That kind of epistemic honesty is appropriate and too rare in supplement content. The same standard applies here.

Beyond the Stomach: Intestinal Barrier and IBD Research

Lion's mane gut health research extends past the stomach into the intestine — specifically the intestinal barrier (what some call the "gut lining") and inflammatory bowel conditions like ulcerative colitis and Crohn's disease.

The intestinal barrier is maintained by proteins that seal the gaps between intestinal cells and prevent bacteria and toxins from passing into the bloodstream. When these proteins degrade, gut permeability increases — a state that some researchers associate with chronic disease states, though the clinical significance of mild permeability increases is still debated.

Preclinical data from animal research shows H. erinaceus polysaccharides can preserve or restore these barrier proteins under conditions of gut injury. Tian et al. (2023) specifically measured the tight-junction proteins occludin and ZO-1 in lion's mane-treated immunocompromised mice and found restoration of the intestinal barrier after cyclophosphamide-induced injury.^[8] For the molecular detail on this mechanism, see lion's mane and leaky gut: intestinal barrier integrity research.

On the IBD side, multiple rodent studies and one non-human primate study — Ren et al. (2023), in cynomolgus monkeys — have shown lion's mane extracts reduce colitis severity, suppress inflammatory signaling through the NF-kB pathway (the main molecular switch for gut inflammation), and restore gut bacteria diversity.^[9] The primate data is significant because it represents a closer model to human biology than rodent studies alone. For the full IBD evidence, see lion's mane and inflammatory bowel disease: preclinical evidence.

Understanding why lion's mane might affect the gut at a molecular level — the pharmacology of its polysaccharides and erinacines — is covered in the pharmacology of Hericium erinaceus: how lion's mane works in the body.

What Lion's Mane Gut Health Research Actually Establishes

Across the full body of research, a clear pattern emerges: the mechanism is biologically plausible, the animal data is consistent, and the human data is minimal.

Two independent systematic reviews — Gravina 2023 from gastroenterologists in a GI journal,^[1] and Menon 2025 across 26 studies^[2] — both confirm gut health as a legitimate area of lion's mane research. Neither overstates the human evidence.

Evidence quality — lion's mane for gut health

1. Cell & Lab Studiescompleted

   Gastric-cell model of chronic atrophic gastritis (Wang 2015, EP-1), GI cancer cell lines (Li 2014), and in-vitro inhibition of six H. pylori strains at MIC ≈ 2 mg/mL (Wang 2019)

2. Animal Studiescompleted

   Rat TNBS colitis (Diling 2017), tumor xenografts (Li 2014), tight-junction repair in immunocompromised mice (Tian 2023), H. pylori colonization down in mice (Wang 2019), and ulcerative colitis relief in cynomolgus monkeys (Ren 2023)

3. Case Reports & Early Seriesmissing

   No published case reports of lion's mane used for a specific human gut condition

4. Small Human Trialscurrent

   One uncontrolled 13-person, two-week pilot (Xie 2021) — microbiota composition and blood chemistry only, no clinical gut-disease endpoint

5. Large Randomized Trialsmissing

   No RCT has tested lion's mane for gastritis, H. pylori eradication, IBD, or any other gut condition

6. Meta-Analyses & Systematic Reviewsmissing

   The two systematic reviews (Gravina 2023; Menon 2025) synthesize preclinical and pilot data — there are no gut-outcome clinical trials to pool

For gut health specifically, the evidence has climbed only to a single uncontrolled pilot. Cell and animal rungs are well populated; case reports, controlled trials, and clinical meta-analyses are all empty. The systematic reviews confirm the research area is legitimate — they cannot substitute for the human trials that have not been run.

Wang 2015; Li 2014; Wang 2019; Diling 2017; Tian 2023; Ren 2023; Xie 2021; Gravina 2023; Menon 2025

What this means practically: the biological mechanisms demonstrated in cell and animal studies are real in the sense that they have been reproduced under controlled conditions. Whether they operate at similar magnitudes in people taking oral supplements is an open question.

Two factors complicate translating animal findings to humans for gut health specifically. First, dosing: the effective doses in animal models don't map directly to human equivalent doses that are practical to achieve through supplementation. Second, preparation: gut health research predominantly uses fruiting body extracts or isolated polysaccharides. Many commercial lion's mane supplements use mycelium grown on grain, which has a substantially different polysaccharide profile. This distinction matters when interpreting whether the research applies to a given product. For more on this, see fruiting body vs. mycelium on grain: the consumer guide.

The honest summary: lion's mane has a stronger and more mechanistically coherent case for gut health than most medicinal mushrooms, backed by a credible scientific review and consistent preclinical data. Human clinical trials have not yet been conducted. That gap is real, and the research doesn't close it.

Using this research responsibly

Moderate

Do not substitute lion's mane for treatment of a diagnosed gut condition

Concern

H. pylori infection, chronic atrophic gastritis, and inflammatory bowel disease are serious conditions with established medical treatments. The lion's mane gut-health evidence is preclinical, with a single small human pilot — it does not support using the mushroom in place of antibiotic eradication therapy, prescribed IBD medication, or clinical monitoring.

What the research says

Treat lion's mane as a research-stage supplement, not a therapy. If you have persistent stomach pain, a known H. pylori infection, or diagnosed IBD, follow the treatment plan set by your clinician and raise any supplement use with them first.

Particularly relevant for: Anyone with a diagnosed or suspected gastrointestinal condition

What to do

Talk to a gastroenterologist or primary-care clinician before adding lion's mane for a gut concern. This article is educational and is not medical advice.

Gravina et al. (2023); Menon et al. (2025)

The Bottom Line

Lion's mane gut health research identifies three consistent mechanisms in preclinical studies: gastroprotection, H. pylori inhibition, and gut microbiota modulation toward beneficial bacterial species. The most authoritative review — Gravina et al., 2023, published in the World Journal of Gastroenterology by practicing gastroenterologists — concludes that traditional GI uses are supported by emerging laboratory evidence, with encouraging early human pilot data. The human evidence remains a single pilot study of 13 participants over two weeks. No clinical trial has tested lion's mane for any gut condition in humans.

Frequently Asked Questions

Is lion's mane mushroom good for gut health?

Preclinical research supports three lion's mane gut mechanisms: protecting the stomach lining, inhibiting H. pylori bacteria, and promoting beneficial gut bacteria growth. The 2023 Gravina review in the World Journal of Gastroenterology, written by gastroenterologists, concluded that traditional GI uses are supported by emerging preclinical evidence. Human clinical evidence is limited to one pilot study of 13 people over two weeks.

Does lion's mane help with digestion?

The lion's mane research on digestion focuses on stomach lining protection and gut bacteria composition rather than digestive enzyme activity. A 2021 human pilot study (n=13) found two weeks of lion's mane consumption increased gut microbiota diversity and raised short-chain-fatty-acid–producing bacteria associated with a healthy gut lining, alongside shifts in routine blood chemistry. No clinical trials have specifically tested lion's mane for digestive complaints like bloating, gas, or indigestion.

Can lion's mane heal leaky gut?

Animal studies show lion's mane polysaccharides can restore tight junction proteins — the structural proteins that maintain the intestinal barrier and prevent increased gut permeability. Tian et al. (2023) measured the tight-junction proteins occludin and ZO-1 after lion's mane treatment in immunocompromised mice and found restoration of the intestinal barrier following cyclophosphamide-induced injury. No human data exists for lion's mane and intestinal permeability.

Does lion's mane have prebiotic effects?

Animal research consistently shows lion's mane extracts promote beneficial gut bacteria — including short-chain-fatty-acid producers — while reducing pathogenic species, the pattern of a prebiotic effect. A 2017 rat colitis study found this shift occurred alongside reduced inflammatory signaling (lower TNF-alpha and NF-κB). The one human pilot study (n=13, 2 weeks) showed similar bacteria shifts, but a study this small cannot confirm prebiotic effects in humans definitively.

How does lion's mane protect the stomach lining?

Wang et al. (2015) found that an isolated polysaccharide (EP-1) from lion's mane mycelium suppressed the growth of transformed, pre-cancerous gastric epithelial cells in a chronic atrophic gastritis cell model, driving them into cell-cycle arrest. Chronic atrophic gastritis is defined by exactly this kind of abnormal transformation of the stomach lining, which is why the result is relevant — though it is a cell-model finding, not evidence from a living stomach. Traditional Chinese medicine specifically used lion's mane for epigastric pain from chronic gastritis — an indication that laboratory research is now examining at the molecular level.

Sources & References

1. 1RTHM-01700·Gravina, Antonietta Gerarda et al. (2023). “Hericium erinaceus, a medicinal fungus with a centuries-old history: Evidence in gastrointestinal diseases..” World journal of gastroenterology.Study breakdown →PubMed →↩
2. 2RTHM-00943·Menon, Arya et al. (2025). “Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review..” Frontiers in nutrition.Study breakdown →PubMed →↩
3. 3RTHM-01458·Xie, Xiao-Qian et al. (2021). “Influence of Short-Term Consumption of Hericium erinaceus on Serum Biochemical Markers and the Changes of the Gut Microbiota: A Pilot Study..” Nutrients.Study breakdown →PubMed →↩
4. 4RTHM-00408·Wang, Mingxing et al. (2015). “A polysaccharide from cultured mycelium of Hericium erinaceus and its anti-chronic atrophic gastritis activity..” International journal of biological macromolecules.Study breakdown →PubMed →↩
5. 5RTHM-00614·Li, Guang et al. (2014). “Anticancer potential of Hericium erinaceus extracts against human gastrointestinal cancers..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
6. 6RTHM-00470·Diling, Chen et al. (2017). “Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota..” Oncotarget.Study breakdown →PubMed →↩
7. 7RTHM-00592·Wang, Ge et al. (2019). “In Vitro and In Vivo Inhibition of Helicobacter pylori by Ethanolic Extracts of Lion's Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
8. 8RTHM-01803·Tian, Baoming et al. (2023). “Ameliorating effects of Hericium erinaceus polysaccharides on intestinal barrier injury in immunocompromised mice induced by cyclophosphamide..” Food & function.Study breakdown →PubMed →↩
9. 9RTHM-01776·Ren, Zhengyu et al. (2023). “Hericium erinaceus mycelium-Derived Polysaccharide Alleviates Ulcerative Colitis and Modulates Gut Microbiota in Cynomolgus Monkeys..” Molecular nutrition & food research.Study breakdown →PubMed →↩